Dapsone D8
| Product Name | Dapsone D8 |
|---|---|
| Alternate Names | Dapsone Stable Isotopes, Stable Isotopes of Dapsone |
| CAT No. | CS-O-06528 |
| CAS No. | 557794-38-4 |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 256.35 g/mol |
| Mol. For. | C₁₂H₄D₈N₂O₂S |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Dapsone |
| Purity | Not less than 90 % |
| Smileys | O=[S](C(C([2H])=C1[2H])=C(C([2H])=C1N)[2H])(C(C([2H])=C2[2H])=C(C([2H])=C2N)[2H])=O |
| Canonical Smiles | C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N |
| InchIKey | MQJKPEGWNLWLTK-PGRXLJNUSA-N |
| Inchl | InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2/i1D,2D,3D,4D,5D,6D,7D,8D |
| IUPAC | 4-(4-amino-2,3,5,6-tetradeuteriophenyl)sulfonyl-2,3,5,6-tetradeuterioaniline |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Dapsone D8 is a deuterated form of dapsone, an antibacterial and anti-inflammatory drug used to treat a variety of skin conditions, including leprosy, dermatitis herpetiformis, and acne vulgaris. Deuterated drugs are modified versions of existing drugs where some of the hydrogen atoms are replaced with deuterium, a stable, non-radioactive isotope of hydrogen. This modification can improve the drug's efficacy, safety, and pharmacokinetics.
Dapsone D8 has the same chemical formula as dapsone, C12H8D8N2O2S, but with eight deuterium atoms replacing eight hydrogen atoms. Deuterium is twice as heavy as hydrogen, which can affect the drug's metabolism, distribution, and elimination in the body. Studies have shown that dapsone D8 has a longer half-life and reduced toxicity compared to dapsone in animal models.
Dapsone D8 is typically administered orally in tablet form, with a recommended dosage of 50-100 mg per day, depending on the patient's condition and response to treatment. It works by inhibiting the synthesis of dihydrofolic acid, a precursor to DNA and RNA, thereby preventing the growth and replication of bacteria and reducing inflammation.
While dapsone D8 is generally well-tolerated, it can cause side effects such as nausea, vomiting, headache, and dizziness. It can also interact with other drugs, including rifampin, phenobarbital, and anticonvulsants, and should be used with caution in patients with glucose-6-phosphate dehydrogenase deficiency. Overall, dapsone D8 is a promising drug candidate with potential applications in treating a variety of skin disorders.
Get an Instant Quote
Related Compounds
Dapsone 13C12 | Dapsone D8 DiHydrochloride | N-Acetyl Dapsone D4 | N-Acetyl Dapsone D8 | Monoacetyl Dapsone-d8 | Dapsone-15N2 | Dapsone D4 | Dapsone 13C12 | Dapsone hydroxylamine-D4 |